The Latest Breaking News on Pharma

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

While the country awaits federal approval of a new ALS drug, people in South Florida with the disease already are using it.

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

Advertising promoting new drugs is effective but often leads to inappropriate prescribing. To protect the health of their citizens, countries should ban it.

Aaron Broussard was sentenced to life in prison for 11 deaths that were tied to controlled substances he sold. Those who died thought they were taking Adderall, but they actually ingested fentanyl.

Gambia on Tuesday ordered importers and shops to suspend sales of all brands of paracetamol syrup while the government investigates a suspected link between the medicine and the deaths of dozens of young children.

A three-storey lab site was approved earlier today

Over the last six years, the vast majority of overdose deaths in British Columbia have been driven by impurities in street drugs

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC). Mersana shares traded as high as 1.79 percent, in a range of $7.48 to $7.94 on day…